The market for cardiovascular medical devices is growing at a fast pace due to the increasing incidence of cardiovascular diseases. This market is growing at the rate of 15% on a year-on-year basis and makes up about 1.7% of the global medical devices market. The medical devices industry requires state of the art devices since a marginal difference can greatly influence the outcomes. The government should restore MEIS initiatives to earlier year percentages to make the business and export more lucrative. Relisys lives up to this expectation by constantly adding more products and expanding its geographic presence.
Certification in the Market
Navin Rajpal, COO, Relisys Medical devices, says, “We are an ISO13485 certified company with all our products CE approved and I think we have laid a very strong foundation. We are growing in multiple verticals such as contract manufacturing and components for various medical specialities. We have been able to work with doctors for improvement of the existing products and develop new ones, where there is 100% dependence on imports.Our products are commercialised currently in over 28 countries and by the end of FY’22 we will be present in 40 countries”. Relisys is also recognized by the Department of Science and Technology in India, which gives it a competitive edge in the market.
Products andthe Framework
Navin adds, “Relisys is the only fully backward integrated facility in this part of the world. We started off as a coronary device manufacturer but now are evolving as a vascular access solution company. We are manufacturing many kinds of catheters, tubing and braiding for various applications as a finished product or as a component. We have a complete range of DES, bare metal stents, a complete balloon catheter range and we are also one of the largest exporter of stents in the B2B segment”. Relisys is also in the process of manufacturing transcatheter heart valves which would be followed by the introduction of the ViennaAortic and the Tric Valve Bicaval Valves system.
Relisys, department of Research and Development always strives towards the innovation of new products while simultaneously improvising on the existing products. This is achieved through diligent execution of Post Market Surveillance protocols, which monitors the effectiveness of the existing products in the market. Relisys also ensures compliance with international standards and regulatory requirements. Navin emphasizes, “Our Strength comes from stringent quality control measures. We use best in class equipment to manufacture medical devices where extreme precision is required. In our pursuit to achieve excellence in all that we do, we continuously introspect, analyse and adapt.” The key equipment used in the manufacturing stage all comply with 21 CFR Part 11 prerequisites since they are all imported from the best companies in their respective sectors. Prioritising the health and safety of our employees has also been of the key values of our company.
India could be a leader in the development, manufacturing and commercialization of affordable medical devices for developing countries in emerging markets
Future Projections
Relisys is undergoing a business expansion in the field of CE marked stent systems and is gradually increasing its reach in the global market while having a wide array of cardiovascular medical devices in order to meet the increasing demand. Relisys prioritizes performance and efficacy while providing its services to its customers and ensuring the safety of its patients. Relisys short-term goal is to grow faster than the market and maintain sufficient revenue generation and vision is to become the best in manufacturing evolution and commercialization of the medical devices in the Indian industry as well as in other countries.
